Impact of XXXX and Hemoglobin A1C on Outcome After Transcatheter Aortic Valve Implantation.

@entity1 @entity4051 @entity6 @entity886 @entity472
UNASSIGNED: Surgical aortic valve replacement (SAVR) is associated with an increased mortality risk in elderly or high-risk @entity1 . Transcatheter @entity886 (TAVI) is an alternative to surgery in @entity1 with symptomatic severe @entity472 who are inoperable or at high operative risk. The impact of @entity6 ( @entity6 ) on @entity1 referred to TAVI merits further investigation. The aim of our study was to evaluate the clinical characteristics and the impact of @entity6 status on the updated Valve Academic Research Consortium 2-defined outcomes of TAVI and to stratify @entity1 outcomes according to their initial glycated hemoglobin (HbA1c) levels. We enrolled and stratified @entity1 who underwent TAVI at our institution according to @entity6 status. A total of 586 @entity1 were enrolled: 348 (59%) without @entity6 and 238 (41%) with @entity6 . There were no significant differences in 30-day mortality @entity1 with @entity6 compared to @entity1 without @entity6 (3.3% vs 2.9%, p  =  0.974). Insulin-treated @entity6 was not associated with adverse outcome in comparison to orally treated @entity6 . To delineate the prognostic power of @entity4051 C in these @entity1 , the cohort was divided into 3 groups according to HbA1C levels (<5.7%, 5.7% to 6.49%, and >= 6.5%). @entity1 with HbA1C >= 6.5% were at increased risk for mortality during follow-up (hazard ratio 2.571, 95% confidence interval 1.077 to 6.136, p  = 0.033) compared to @entity1 with HbA1C <5.7%. In conclusion, unlike SAVR, @entity6 is not associated with an increased mortality risk after TAVI, nor is it associated with increased complications rates. A more poorly controlled disease, as manifested by elevated HbA1c levels, may be associated with increased mortality during long-term follow-up.
